SynthesisPloS one2014
Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29,464 patients.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies.Prostate cancer and prostatic diseases · 2025Pooled it
- Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen.Cancer causes & control : CCC · 2020Pooled it
- Pooled it
- Trial
- Exosomes That Have Different Cellular Origins Followed by the Impact They Have on Prostate Tumor Development in the Tumor Microenvironment.Cancer reports (Hoboken, N.J.) · 2024Review
- Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy.Exploration of targeted anti-tumor therapy · 2024Review
- Review
- Obesity-Related Cross-Talk between Prostate Cancer and Peripheral Fat: Potential Role of Exosomes.Cancers · 2022Review
- Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.British journal of cancer · 2022Article
- Association between obesity and frequency of high-grade prostate cancer on biopsy in men: A single-center retrospective study.Molecular and clinical oncology · 2022Article
- Extreme body mass index is associated with poor survival outcomes after radical cystectomy: a retrospective cohort study in a Chinese population.Translational andrology and urology · 2021Article
- The role of nutritional interventions in prostate cancer: A review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021Review
- Article
- Adipose Tissue, Obesity and Adiponectin: Role in Endocrine Cancer Risk.International journal of molecular sciences · 2019Review
- Altered circulating levels of adipokine omentin-1 in patients with prostate cancer.OncoTargets and therapy · 2019Article
- Obesity, Type-2 Diabetes and Cancer: Mechanistic Insights.Critical reviews in oncogenesis · 2019Review
- Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study.Oncotarget · 2018Article
- Differential expressions of integrin-linked kinase, β-parvin and cofilin 1 in high-fat diet induced prostate cancer progression in a transgenic mouse model.Oncology letters · 2018Article
- High-fat diet-induced adipokine and cytokine alterations promote the progression of prostate cancerOncology letters · 2018Article
- Optimal biopsy strategy for prostate cancer detection by performing a Bayesian network meta-analysis of randomized controlled trials.Journal of Cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesIn previous studies, obesity (measured according to the body mass index) has correlated inconsistently with the risk of biopsy-measured prostate cancer, and specifically high-grade prostate cancer. This meta-analysis aimed to clarify these correlations.
methodsA comprehensive literature search of the MEDLINE and EMBASE databases was conducted for relevant studies published through January 2014. The pooled estimates of odds ratios (OR) and confidence intervals (CI) were computed, and the meta-analysis was performed with the STATA software according to a random effects approach.
resultsA total of 11 studies that included 29,464 individuals were identified. A 5-kg/m2 increase in body mass index was associated with a 15% (OR, 1.15; 95% CI, 0.98-1.34) higher risk of prostate cancer detection and a 37% (OR, 1.37; 95% CI, 1.19-1.57) higher risk of high-grade prostate cancer detection at biopsy. There were no differences among the results of studies conducted in the USA, Europe or Asia. We also found that studies that had adjusted for prostate-specific antigen levels, digital rectal examination results, and prostate volumes obtained positive significant outcomes (OR, 1.27; 95% CI, 1.12-1.44), whereas studies that did not adjust for the above-mentioned confounding variables obtained negative results (OR, 0.92; 95% CI, 0.68-1.25). Moreover, the positive correlation between body mass index and the detection of both prostate cancer and high-grade diseases tended to be stronger as the number of biopsy cores increased.
conclusionThe present meta-analysis demonstrated that a high body mass index correlated positively with prostate cancer detection, especially high-grade prostate cancer detection. The adoption of a modified and possibly more aggressive biopsy strategy was suggested for obese populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.